Efficacy of Various Treatments for Acute Acoustic Trauma.
Efficacy of Various Treatments for Acute Acoustic Trauma in the Israeli Defense Force.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Haifa, Israel
- Israeli Navy Medical Institute
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Subjects diagnosed with acute acoustic trauma.
- Hearing exam performed at least 24 hours after acute acoustic trauma.
- There was a reduction of at least 30dB in the 3,000-8,000 Hz frequency range in the first hearing exam performed.
Exclusion Criteria:
- A known hearing impairment prior to acute acoustic trauma.
- Subjects lost from follow up.
- Another diagnosis is more likely than hearing loss due to acute acoustic trauma.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
No treatment
|
No intervention - retrospective study
|
|
Steroids only - early
treatment was initiated within 7 days of acoustic trauma.
|
No intervention - retrospective study
|
|
Early combined steroid and hyperbaric oxygen therapy
treatment was initiated within 7 days of acoustic trauma.
|
No intervention - retrospective study
|
|
Delayed combined steroid and hyperbaric oxygen therapy
treatment was initiated after 7 days of acoustic trauma.
|
No intervention - retrospective study
|
|
Early sequential steroid followed by HBO therapy
treatment was initiated within 7 days of acoustic trauma.
|
No intervention - retrospective study
|
|
Delayed sequential steroid followed by HBO therapy
treatment was initiated after 7 days of acoustic trauma.
|
No intervention - retrospective study
|
|
Hyperbaric oxygen therapy only
|
No intervention - retrospective study
|
|
Steroid only - delayed
treatment was initiated after 7 days of acoustic trauma.
|
No intervention - retrospective study
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Hearing improvement
Time Frame: until 1 year of acoustic trauma.
|
dB
|
until 1 year of acoustic trauma.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Tinnitus
Time Frame: until 1 year of acoustic trauma.
|
Qualitative - subjective
|
until 1 year of acoustic trauma.
|
|
Otoacoustic Emissions (OAE)
Time Frame: until 1 year of acoustic trauma.
|
dB
|
until 1 year of acoustic trauma.
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2131-2020
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.